{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:47:19Z","timestamp":1767340039693,"version":"3.37.3"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are two of the most commonly used antihypertensive drugs acting on the renin\u2013angiotensin\u2013aldosterone system (RAAS). Previous research has shown that RAAS inhibitors increase the expression of angiotensin-converting enzyme, a cellular receptor for the severe acute respiratory syndrome coronavirus 2, raising concerns that the use of ACEi and ARBs in hypertensive patients may increase COVID-19 patient mortality. Therefore, the main aim of the current study was to find out the role of drugs acting on RAAS, particularly ACEi\/ARBs in the deaths of COVID-19 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 68 studies were found to be appropriate, reporting a total of 128,078 subjects. The odds ratio was found to be 1.14 [0.95, 1.36], which indicates the non-significant association of ACEi\/ARBs with mortality of COVID-19 patients. Further, the association of individual ACEi\/ARBs with mortality of COVID-19 patients was also found non-significant. The sensitivity analysis results have shown no significant effect of outliers on the outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on available evidence, ACEi\/ARB were not significantly associated with deaths of COVID-19 patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-022-00303-8","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T22:02:42Z","timestamp":1662501762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drugs acting on the renin\u2013angiotensin\u2013aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies"],"prefix":"10.1186","volume":"74","author":[{"given":"Ruchika","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7806-9986","authenticated-orcid":false,"given":"Anoop","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaseela","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit K.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"issue":"13","key":"303_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323(13):1239\u20131242. https:\/\/doi.org\/10.1001\/jama.2020.2648","journal-title":"JAMA"},{"key":"303_CR2","unstructured":"World Health Organization (WHO) Weekly epidemiological update on COVID-19 - 15 March 2022. https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---15-march-2022. Accessed 17 Mar 2022"},{"key":"303_CR3","doi-asserted-by":"publisher","unstructured":"Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M (2020) Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2(8):1069\u20131076. https:\/\/doi.org\/10.1007\/s42399-020-00363-4","DOI":"10.1007\/s42399-020-00363-4"},{"issue":"2","key":"303_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271-280.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"issue":"8","key":"303_CR5","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s11739-020-02436-7","volume":"15","author":"A Albini","year":"2020","unstructured":"Albini A, Noonan DM, Pelosi G, Di Guardo G, Lombardo M (2020) The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies-reply. Intern Emerg Med 15(8):1583\u20131584. https:\/\/doi.org\/10.1007\/s11739-020-02436-7","journal-title":"Intern Emerg Med"},{"issue":"12","key":"303_CR6","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J et al (2020) Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126(12):1671\u20131681. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317134","journal-title":"Circ Res"},{"issue":"10","key":"303_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/ajh\/hpaa096","volume":"33","author":"C Felice","year":"2020","unstructured":"Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, Romagnoli M, Tonon L, Cavasin P, Novello S, Scarpa R, Farnia A, De Menis E, Rigoli R, Cinetto F, Pauletto P, Agostini C, Rattazzi M (2020) Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian Cohort of 133 hypertensives. Am J Hypertens 33(10):944\u2013948. https:\/\/doi.org\/10.1093\/ajh\/hpaa096","journal-title":"Am J Hypertens"},{"issue":"2","key":"303_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosb\u00f8l","year":"2020","unstructured":"Fosb\u00f8l EL, Butt JH, \u00d8stergaard L, Andersson C, Selmer C, Kragholm K, Schou M, Phelps M, Gislason GH, Gerds TA, Torp-Pedersen C, K\u00f8ber L (2020) Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA 324(2):168\u2013177. https:\/\/doi.org\/10.1001\/jama.2020.11301","journal-title":"JAMA"},{"issue":"6","key":"303_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jinf.2020.05.056","volume":"81","author":"J Hu","year":"2020","unstructured":"Hu J, Zhang X, Zhang X, Zhao H, Lian J, Hao S, Jia H, Yang M, Lu Y, Xiang D, Cai H, Zhang S, Gu J, Ye C, Yu G, Jin C, Zheng L, Yang Y, Sheng J (2020) COVID-19 is more severe in patients with hypertension; ACEI\/ARB treatment does not influence clinical severity and outcome. J Infect 81(6):979\u2013997. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.056","journal-title":"J Infect"},{"issue":"7","key":"303_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(7):811\u2013818. https:\/\/doi.org\/10.1001\/jamacardio.2020.1017","journal-title":"JAMA Cardiol"},{"issue":"1","key":"303_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/fcp.12613","volume":"35","author":"M Lafaurie","year":"2021","unstructured":"Lafaurie M, Martin-Blondel G, Delobel P, Charpentier S, Sommet A, Moulis G (2021) Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. Fundam Clin Pharmacol 35(1):194\u2013203. https:\/\/doi.org\/10.1111\/fcp.12613","journal-title":"Fundam Clin Pharmacol"},{"issue":"7","key":"303_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"303_CR13","unstructured":"STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines. Available at https:\/\/www.strobe-statement.org\/"},{"key":"303_CR14","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013, http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"4","key":"303_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248080","volume":"16","author":"CG Derington","year":"2021","unstructured":"Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021) Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE 16(4):e0248080. https:\/\/doi.org\/10.1371\/journal.pone.0248080","journal-title":"PLoS ONE"},{"issue":"2","key":"303_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000513047","volume":"30","author":"M Ayed","year":"2021","unstructured":"Ayed M, Borahmah AA, Yazdani A, Sultan A, Mossad A, Rawdhan H (2021) Assessment of clinical characteristics and mortality-associated factors in COVID-19 critical cases in Kuwait. Med Princ Pract 30(2):185\u2013192. https:\/\/doi.org\/10.1159\/000513047","journal-title":"Med Princ Pract"},{"key":"303_CR17","doi-asserted-by":"publisher","unstructured":"Senkal N, Meral R, Medetalibeyo\u011flu A, Konyao\u011flu H, Kose M, Tukek T (2020) Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19. Anatol J Cardiol 24(1):21\u201329. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2020.57431","DOI":"10.14744\/AnatolJCardiol.2020.57431"},{"key":"303_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.amjcard.2020.07.007","volume":"132","author":"DJ Bae","year":"2020","unstructured":"Bae DJ, Tehrani DM, Rabadia SV, Frost M, Parikh RV, Calfon-Press M, Aksoy O, Umar S, Ardehali R, Rabbani A, Bokhoor P, Nsair A, Currier J, Tobis J, Fonarow GC, Dave R, Rafique AM (2020) Angiotensin converting enzyme inhibitor and angiotensin II receptor blocker use among outpatients diagnosed with COVID-19. Am J Cardiol 132:150\u2013157. https:\/\/doi.org\/10.1016\/j.amjcard.2020.07.007","journal-title":"Am J Cardiol"},{"key":"303_CR19","doi-asserted-by":"publisher","unstructured":"Baker KF, Hanrath AT, van der Loeff IS, Tee SA, Capstick R, Marchitelli G, Li A, Barr A, Eid A, Ahmed S, Bajwa D, Mohammed O, Alderson N, Lendrem C, Lendrem DW, Covid-Control Group, Covid-Clinical Group, Pareja-Cebrian L, Welch A, Field J, Payne BAI, Taha Y, Price DA, Gibbins C, Schmid ML, Hunter E, Duncan CJA (2021) COVID-19 management in a UK NHS foundation trust with a high consequence infectious diseases centre: a retrospective analysis. Med Sci (Basel) 9(1):6. https:\/\/doi.org\/10.3390\/medsci9010006","DOI":"10.3390\/medsci9010006"},{"issue":"6","key":"303_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.kint.2020.03.018","volume":"97","author":"D Banerjee","year":"2020","unstructured":"Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M (2020) COVID-19 infection in kidney transplant recipients. Kidney Int 97(6):1076\u20131082. https:\/\/doi.org\/10.1016\/j.kint.2020.03.018","journal-title":"Kidney Int"},{"issue":"1","key":"303_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jch.14101","volume":"23","author":"AZ Bauer","year":"2021","unstructured":"Bauer AZ, Gore R, Sama SR, Rosiello R, Garber L, Sundaresan D, McDonald A, Arruda P, Kriebel D (2021) Hypertension, medications, and risk of severe COVID-19: a Massachusetts community-based observational study. J Clin Hypertens (Greenwich) 23(1):21\u201327. https:\/\/doi.org\/10.1111\/jch.14101","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"303_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/ejhf.1924","volume":"22","author":"DM Bean","year":"2020","unstructured":"Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A, Folarin A, Roguski L, Noor K, Shek A, Zakeri R, Shah AM, Teo JTH, Dobson RJB (2020) Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail 22(6):967\u2013974. https:\/\/doi.org\/10.1002\/ejhf.1924","journal-title":"Eur J Heart Fail"},{"key":"303_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100660","volume":"31","author":"P Braude","year":"2020","unstructured":"Braude P, Carter B, Short R, Vilches-Moraga A, Verduri A, Pearce L, Price A, Quinn TJ, Stechman M, Collins J, Bruce E, Einarsson A, Rickard F, Mitchell E, Holloway M, Hesford J, Barlow-Pay F, Clini E, Myint PK, Moug S, McCarthy K, Hewitt J (2020) The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. Int J Cardiol Heart Vasc 31:100660. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100660","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"6","key":"303_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ehjcvp\/pvaa056","volume":"6","author":"F Cannata","year":"2020","unstructured":"Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, Viggiani G, Panico C, Regazzoli D, Ciccarelli M, Voza A, Aghemo A, Li H, Wang Y, Condorelli G, Stefanini GG (2020) Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother 6(6):412\u2013414. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa056","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"303_CR25","doi-asserted-by":"publisher","unstructured":"Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, Amadou C, Arnault G, Baudoux F, Bauduceau B, Borot S, Bourgeon-Ghittori M, Bourron O, Boutoille D, Cazenave-Roblot F, Chaumeil C, Cosson E, Coudol S, Darmon P, Disse E, Ducet-Boiffard A, Gaborit B, Joubert M, Kerlan V, Laviolle B, Marchand L, Meyer L, Potier L, Prevost G, Riveline JP, Robert R, Saulnier PJ, Sultan A, Th\u00e9baut JF, Thivolet C, Tramunt B, Vatier C, Roussel R, Gautier JF, Gourdy P; CORONADO investigators (2020) Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63(8):1500\u20131515. https:\/\/doi.org\/10.1007\/s00125-020-05180-x","DOI":"10.1007\/s00125-020-05180-x"},{"key":"303_CR26","doi-asserted-by":"publisher","unstructured":"Cetinkal G, Kocas BB, Ser OS, Kilci H, Yildiz SS, Ozcan SN, Verdi Y, Altinay M, Kilickesmez K (2020) The association between chronic use of renin\u2013angiotensin\u2013aldosterone system blockers and in-hospital adverse events among COVID-19 patients with hypertension. Sisli Etfal Hastan Tip Bul 54(4):399\u2013404. https:\/\/doi.org\/10.14744\/SEMB.2020.15689","DOI":"10.14744\/SEMB.2020.15689"},{"key":"303_CR27","doi-asserted-by":"publisher","unstructured":"Chaudhri I, Koraishy FM, Bolotova O, Yoo J, Marcos LA, Taub E, Sahib H, Bloom M, Ahmad S, Skopicki H, Mallipattu SK (2020) Outcomes associated with the use of renin\u2013angiotensin\u2013aldosterone system blockade in hospitalized patients with SARS-CoV-2 Infection. Kidney360 1(8):801\u2013809. https:\/\/doi.org\/10.34067\/kid.0003792020","DOI":"10.34067\/kid.0003792020"},{"issue":"21","key":"303_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017736","volume":"9","author":"C Chen","year":"2020","unstructured":"Chen C, Wang F, Chen P, Jiang J, Cui G, Zhou N, Moroni F, Moslehi JJ, Ammirati E, Wang DW (2020) Mortality and pre-hospitalization use of renin-angiotensin system inhibitors in hypertensive COVID-19 patients. J Am Heart Assoc 9(21):e017736. https:\/\/doi.org\/10.1161\/JAHA.120.017736","journal-title":"J Am Heart Assoc"},{"key":"303_CR29","doi-asserted-by":"publisher","unstructured":"Chen M, Fan Y, Wu X, Zhang, L, Guo T, Keqiong D, Cao J, Luo H, He T, Gong Y, Wang H, Wan J, Wang X, Lu Z (2020) Clinical characteristics and risk factors for fatal outcome in patients with 2019-coronavirus infected disease (COVID-19) in Wuhan, China (2\/27\/2020). https:\/\/doi.org\/10.2139\/ssrn.3546069","DOI":"10.2139\/ssrn.3546069"},{"issue":"7","key":"303_CR30","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/dc20-0660","volume":"43","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, Liu C, Xiong M, Deng A, Zhang Y, Zheng L, Huang K (2020) Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 43(7):1399\u20131407. https:\/\/doi.org\/10.2337\/dc20-0660","journal-title":"Diabetes Care"},{"key":"303_CR31","doi-asserted-by":"publisher","unstructured":"Choi HK, Koo HJ, Seok H, Jeon JH, Choi WS, Kim DJ, Park DW, Han E (2020) ARB\/ACEI use and severe COVID-19: a nationwide case\u2013control study. medRxiv 2020.06.12.20129916; https:\/\/doi.org\/10.1101\/2020.06.12.20129916","DOI":"10.1101\/2020.06.12.20129916"},{"issue":"4","key":"303_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/thoraxjnl-2020-215768","volume":"76","author":"CF Christiansen","year":"2021","unstructured":"Christiansen CF, Potteg\u00e5rd A, Heide-J\u00f8rgensen U, Bodilsen J, S\u00f8gaard OS, Maeng M, Vistisen ST, Schmidt M, Lund LC, Reilev M, Hallas J, Voldstedlund M, Husby A, Thomsen MK, Johansen NB, Brun NC, Thomsen RW, B\u00f8tker HE, S\u00f8rensen HT (2021) SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case\u2013control and cohort analysis. Thorax 76(4):370\u2013379. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215768","journal-title":"Thorax"},{"issue":"2","key":"303_CR33","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1161\/HYPERTENSIONAHA.120.15312","volume":"76","author":"A Conversano","year":"2020","unstructured":"Conversano A, Melillo F, Napolano A, Fominskiy E, Spessot M, Ciceri F, Agricola E (2020) Renin\u2013angiotensin\u2013aldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: a case series study. Hypertension 76(2):e10\u2013e12. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15312","journal-title":"Hypertension"},{"key":"303_CR34","doi-asserted-by":"publisher","unstructured":"Covino M, De Matteis G, Burzo ML, Santoro M, Fuorlo M, Sabia L, Sandroni C, Gasbarrini A, Franceschi F, Gambassi G; Gemelli Against COVID-19 Group (2020) Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. Intern Med J 50(12):1483\u20131491. https:\/\/doi.org\/10.1111\/imj.15078","DOI":"10.1111\/imj.15078"},{"key":"303_CR35","doi-asserted-by":"publisher","unstructured":"Desai A, Voza G, Paiardi S, Teofilo FI, Caltagirone G, Pons MR, Aloise M, Kogan M, Tommasini T, Savevski V, Stefanini G, Angelini C, Ciccarelli M, Badalamenti S, De Nalda AL, Aghemo A, Cecconi M, Martinelli Boneschi F, Voza A; Humanitas COVID-19 task force (2021) The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: a retrospective, observational study in Northern Italy. Int J Cardiol 324:249\u2013254. https:\/\/doi.org\/10.1016\/j.ijcard.2020.09.062","DOI":"10.1016\/j.ijcard.2020.09.062"},{"issue":"11","key":"303_CR36","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jamda.2020.09.004","volume":"21","author":"B Genet","year":"2020","unstructured":"Genet B, Vidal JS, Cohen A, Boully C, Beunardeau M, Marine Harl\u00e9 L, Gon\u00e7alves A, Boudali Y, Hernandorena I, Bailly H, Lenoir H, Piccoli M, Chahwakilian A, Kermanach L, de Jong L, Duron E, Girerd X, Hanon O (2020) COVID-19 In-hospital mortality and use of renin\u2013angiotensin system blockers in geriatrics patients. J Am Med Dir Assoc 21(11):1539\u20131545. https:\/\/doi.org\/10.1016\/j.jamda.2020.09.004","journal-title":"J Am Med Dir Assoc"},{"key":"303_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104931","volume":"158","author":"A Giacomelli","year":"2020","unstructured":"Giacomelli A, Ridolfo AL, Milazzo L, Oreni L, Bernacchia D, Siano M, Bonazzetti C, Covizzi A, Schiuma M, Passerini M, Piscaglia M, Coen M, Gubertini G, Rizzardini G, Cogliati C, Brambilla AM, Colombo R, Castelli A, Rech R, Riva A, Torre A, Meroni L, Rusconi S, Antinori S, Galli M (2020) 30-Day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study. Pharmacol Res 158:104931. https:\/\/doi.org\/10.1016\/j.phrs.2020.104931","journal-title":"Pharmacol Res"},{"key":"303_CR38","doi-asserted-by":"publisher","unstructured":"Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R; Reggio Emilia COVID-19 Working Group (2020) Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PLoS ONE 15(8):e0238281. https:\/\/doi.org\/10.1371\/journal.pone.0238281","DOI":"10.1371\/journal.pone.0238281"},{"issue":"3","key":"303_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/1074248420976279","volume":"26","author":"HA Hakeam","year":"2021","unstructured":"Hakeam HA, Alsemari M, Duhailib ZA, Ghonem L, Alharbi SA, Almutairy E, Sheraim NMB, Alsalhi M, Alhijji A, AlQahtani S, Khalid M, Barry M (2021) Association of angiotensin-converting enzyme inhibitors and angiotensin II blockers with severity of COVID-19: a multicentre, prospective study. J Cardiovasc Pharmacol Ther 26(3):244\u2013252. https:\/\/doi.org\/10.1177\/1074248420976279","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"303_CR40","doi-asserted-by":"publisher","unstructured":"Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, Zhu C, Song Y, Wang Y, Zou Y, Qian J, Yu K, Gong H, Ge J (2020) The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med 8(7):430. https:\/\/doi.org\/10.21037\/atm.2020.03.229","DOI":"10.21037\/atm.2020.03.229"},{"key":"303_CR41","doi-asserted-by":"publisher","unstructured":"Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, Goldberg SL (2020) Hypertension and renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19. medRxiv 2020.04.24.20077388. https:\/\/doi.org\/10.1101\/2020.04.24.20077388","DOI":"10.1101\/2020.04.24.20077388"},{"key":"303_CR42","doi-asserted-by":"publisher","unstructured":"Jung C, Bruno RR, Wernly B, Joannidis M, Oeyen S, Zafeiridis T, Marsh B, Andersen FH, Moreno R, Fernandes AM, Artigas A, Pinto BB, Schefold J, Wolff G, Kelm M, De Lange DW, Guidet B, Flaatten H, Fj\u00f8lner J; COVIP study group (2021) Inhibitors of the renin\u2013angiotensin\u2013aldosterone system and COVID-19 in critically ill elderly patients. Eur Heart J Cardiovasc Pharmacother 7(1):76\u201377. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa083","DOI":"10.1093\/ehjcvp\/pvaa083"},{"issue":"16","key":"303_CR43","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","volume":"71","author":"SY Jung","year":"2020","unstructured":"Jung SY, Choi JC, You SH, Kim WY (2020) Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)-related outcomes in Korea: a nationwide population-based cohort study. Clin Infect Dis 71(16):2121\u20132128. https:\/\/doi.org\/10.1093\/cid\/ciaa624","journal-title":"Clin Infect Dis"},{"key":"303_CR44","doi-asserted-by":"publisher","unstructured":"Khan KS, Reed-Embleton H, Lewis J, Bain P, Mahmud S (2020) Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study. Scott Med J 65(4):149\u2013153. https:\/\/doi.org\/10.1177\/0036933020951926","DOI":"10.1177\/0036933020951926"},{"key":"303_CR45","doi-asserted-by":"publisher","unstructured":"Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, Spatz ES, Murugiah K, Lin Z, Omer SB, Vojta D, Krumholz HM (2020) Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19. medRxiv. 19:2020.05.17.20104943. https:\/\/doi.org\/10.1101\/2020.05.17.20104943","DOI":"10.1101\/2020.05.17.20104943"},{"key":"303_CR46","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2021004","volume":"43","author":"JH Kim","year":"2021","unstructured":"Kim JH, Baek YH, Lee H, Choe YJ, Shin HJ, Shin JY (2021) Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study. Epidemiol Health 43:e2021004. https:\/\/doi.org\/10.4178\/epih.e2021004","journal-title":"Epidemiol Health"},{"issue":"8","key":"303_CR47","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","volume":"222","author":"KW Lam","year":"2020","unstructured":"Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, Mallipattu SK, Skopicki HA, Singer AJ, Duong TQ (2020) Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis 222(8):1256\u20131264. https:\/\/doi.org\/10.1093\/infdis\/jiaa447","journal-title":"J Infect Dis"},{"key":"303_CR48","doi-asserted-by":"publisher","unstructured":"Lee HY, Ahn J, Kang CK, Won SH, Park JH, Kang CH, Chung KH, Joh JS, Bang J, Yoo, H, Park O, Oh M (2020) Association of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19-related outcome (4\/1\/2020). https:\/\/doi.org\/10.2139\/ssrn.3569837","DOI":"10.2139\/ssrn.3569837"},{"issue":"7","key":"303_CR49","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Chen J, Zhang H, Deng A (2020) Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan. China JAMA Cardiol 5(7):825\u2013830. https:\/\/doi.org\/10.1001\/jamacardio.2020.1624","journal-title":"China JAMA Cardiol"},{"issue":"5","key":"303_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/ehjcvp\/pvaa062","volume":"7","author":"S Liabeuf","year":"2021","unstructured":"Liabeuf S, Moragny J, Bennis Y, Batteux B, Brochot E, Schmit JL, Lanoix JP, Andrejak C, Ganry O, Slama M, Maizel J, Mahjoub Y, Masmoudi K, Gras-Champel V (2021) Association between renin\u2013angiotensin system inhibitors and COVID-19 complications. Eur Heart J Cardiovasc Pharmacother 7(5):426\u2013434. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa062","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"303_CR51","doi-asserted-by":"publisher","first-page":"20250","DOI":"10.1038\/s41598-020-76915-4","volume":"10","author":"JH Lim","year":"2020","unstructured":"Lim JH, Cho JH, Jeon Y, Kim JH, Lee GY, Jeon S, Noh HW, Lee YH, Lee J, Chang HH, Jung HY, Choi JY, Park SH, Kim CD, Kim YL, Kim SW (2020) Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. Sci Rep 10(1):20250. https:\/\/doi.org\/10.1038\/s41598-020-76915-4","journal-title":"Sci Rep"},{"key":"303_CR52","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Otero D, L\u00f3pez-Pais J, Cacho-Antonio CE, Ant\u00fanez-Mui\u00f1os PJ, Gonz\u00e1lez-Ferrero T, P\u00e9rez-Poza M, Otero-Garc\u00eda \u00d3, D\u00edaz-Fern\u00e1ndez B, Bastos-Fern\u00e1ndez M, Bouzas-Cruz N, Sanmart\u00edn-Pena XC, Varela-Rom\u00e1n A, Portela-Romero M, Vald\u00e9s-Cuadrado L, Pose-Reino A, Gonz\u00e1lez-Juanatey JR (2021) Impacto de los inhibidores de la enzima de conversi\u00f3n de la angiotensina y los antagonistas del receptor de la angiotensina II en la COVID-19 en una poblaci\u00f3n occidental. Registro CARDIOVID [Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry]. Rev Esp Cardiol 74(2):175\u2013182. https:\/\/doi.org\/10.1016\/j.recesp.2020.05.030","DOI":"10.1016\/j.recesp.2020.05.030"},{"issue":"11","key":"303_CR53","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","volume":"43","author":"Y Matsuzawa","year":"2020","unstructured":"Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, Tsukahara K, Shimizu H, Iwabuchi K, Yamada Y, Saka K, Takeuchi I, Hirano T, Tamura K (2020) Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res 43(11):1257\u20131266. https:\/\/doi.org\/10.1038\/s41440-020-00535-8","journal-title":"Hypertens Res"},{"issue":"9","key":"303_CR54","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK (2020) Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(9):1020\u20131026. https:\/\/doi.org\/10.1001\/jamacardio.2020.1855","journal-title":"JAMA Cardiol"},{"issue":"1","key":"303_CR55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G (2020) Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 9(1):757\u2013760. https:\/\/doi.org\/10.1080\/22221751.2020.1746200","journal-title":"Emerg Microbes Infect"},{"key":"303_CR56","doi-asserted-by":"publisher","unstructured":"Negreira-Caama\u00f1o M, Piqueras-Flores J, Mart\u00ednez-DelRio J, Nieto-Sandoval-Martin-DeLaSierra P, Aguila-Gordo D, Mateo-Gomez C, Salas-Bravo D, Rodriguez-Martinez M, Negreira-Caama\u00f1o M (2020) Impact of treatment with renin-angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19. High Blood Press Cardiovasc Prev 27(6):561\u2013568. https:\/\/doi.org\/10.1007\/s40292-020-00409-7","DOI":"10.1007\/s40292-020-00409-7"},{"issue":"9","key":"303_CR57","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1093\/cid\/ciaa677","volume":"71","author":"A Oussalah","year":"2020","unstructured":"Oussalah A, Gleye S, Clerc Urmes I, Laugel E, Callet J, Barb\u00e9 F, Orlowski S, Malaplate C, Aimone-Gastin I, Caillierez BM, Merten M, Jeannesson E, Kormann R, Olivier JL, Rodriguez-Gu\u00e9ant RM, Namour F, Bevilacqua S, Losser MR, Levy B, Kimmoun A, Gibot S, Thilly N, Frimat L, Schvoerer E, Gu\u00e9ant JL (2020) Long-term ACE inhibitor\/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the Northeast of France. Clin Infect Dis 71(9):2447\u20132456. https:\/\/doi.org\/10.1093\/cid\/ciaa677","journal-title":"Clin Infect Dis"},{"issue":"3","key":"303_CR58","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1161\/HYPERTENSIONAHA.120.15289","volume":"76","author":"W Pan","year":"2020","unstructured":"Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, He H, Wang Z, Ye D, Zhao M, Luo Z, Liu M, Zhang P, Gu J, Liu M, Li D, Liu J, Wan J (2020) Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients. Hypertension 76(3):732\u2013741. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15289","journal-title":"Hypertension"},{"key":"303_CR59","doi-asserted-by":"publisher","unstructured":"Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Lo Re V, Akgun KM, Crothers K, Taddei TH, Freiberg MS, Justice AC (2020) Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54\u201375 years. medRxiv. 14:2020.04.09.20059964. https:\/\/doi.org\/10.1101\/2020.04.09.20059964","DOI":"10.1101\/2020.04.09.20059964"},{"issue":"12","key":"303_CR60","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1111\/bcp.14873","volume":"87","author":"E Rezel-Potts","year":"2021","unstructured":"Rezel-Potts E, Douiri A, Chowienczyk PJ, Gulliford MC (2021) Antihypertensive medications and COVID-19 diagnosis and mortality: population-based case-control analysis in the United Kingdom. Br J Clin Pharmacol 87(12):4598\u20134607. https:\/\/doi.org\/10.1111\/bcp.14873","journal-title":"Br J Clin Pharmacol"},{"key":"303_CR61","doi-asserted-by":"publisher","unstructured":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 323(20):2052\u20132059. https:\/\/doi.org\/10.1001\/jama.2020.6775","DOI":"10.1001\/jama.2020.6775"},{"issue":"10","key":"303_CR62","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/jcm9103136","volume":"9","author":"E Rodilla","year":"2020","unstructured":"Rodilla E, Saura A, Jim\u00e9nez I, Mendiz\u00e1bal A, Pineda-Cantero A, Lorenzo-Hern\u00e1ndez E, Fidalgo-Montero MDP, L\u00f3pez-Cuervo JF, Gil-S\u00e1nchez R, Rabad\u00e1n-Pejenaute E, Abella-V\u00e1zquez L, Giner-Galva\u00f1 V, Sol\u00eds-Marqu\u00ednez MN, Boixeda R, Pe\u00f1a-Fern\u00e1ndez A, Carrasco-S\u00e1nchez FJ, Gonz\u00e1lez-Moraleja J, Torres-Pe\u00f1a JD, Guisado-Espartero ME, Escobar-Sevilla J, Guzm\u00e1n-Garc\u00eda M, Mart\u00edn-Escalante MD, Mart\u00ednez-Gonz\u00e1lez \u00c1L, Casas-Rojo JM, G\u00f3mez-Huelgas R (2020) Association of hypertension with all-cause mortality among hospitalized patients with COVID-19. J Clin Med 9(10):3136. https:\/\/doi.org\/10.3390\/jcm9103136","journal-title":"J Clin Med"},{"issue":"12","key":"303_CR63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29058","volume":"3","author":"N Rosenthal","year":"2020","unstructured":"Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S (2020) Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open 3(12):e2029058. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.29058","journal-title":"JAMA Netw Open"},{"issue":"17","key":"303_CR64","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016948","volume":"9","author":"C Sardu","year":"2020","unstructured":"Sardu C, Maggi P, Messina V, Iuliano P, Sardu A, Iovinella V, Paolisso G, Marfella R (2020) Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy. J Am Heart Assoc 9(17):e016948. https:\/\/doi.org\/10.1161\/JAHA.120.016948","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"303_CR65","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/10641963.2020.1783549","volume":"42","author":"M Sel\u00e7uk","year":"2020","unstructured":"Sel\u00e7uk M, \u00c7\u0131nar T, Keskin M, \u00c7i\u00e7ek V, K\u0131l\u0131\u00e7 \u015e, Kenan B, Do\u011fan S, Asal S, G\u00fcnay N, Y\u0131ld\u0131r\u0131m E, Keskin \u00dc, Orhan AL (2020) Is the use of ACE inb\/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients? Clin Exp Hypertens 42(8):738\u2013742. https:\/\/doi.org\/10.1080\/10641963.2020.1783549","journal-title":"Clin Exp Hypertens"},{"issue":"12","key":"303_CR66","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1097\/HJH.0000000000002584","volume":"38","author":"P Shah","year":"2020","unstructured":"Shah P, Owens J, Franklin J, Jani Y, Kumar A, Doshi R (2020) Baseline use of angiotensin-converting enzyme inhibitor\/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients. J Hypertens 38(12):2537\u20132541. https:\/\/doi.org\/10.1097\/HJH.0000000000002584","journal-title":"J Hypertens"},{"issue":"12","key":"303_CR67","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/ajh\/hpaa149","volume":"33","author":"A Soleimani","year":"2020","unstructured":"Soleimani A, Kazemian S, Karbalai Saleh S, Aminorroaya A, Shajari Z, Hadadi A, Talebpour M, Sadeghian H, Payandemehr P, Sotoodehnia M, Bahreini M, Najmeddin F, Heidarzadeh A, Zivari E, Ashraf H (2020) Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19. Am J Hypertens 33(12):1102\u20131111. https:\/\/doi.org\/10.1093\/ajh\/hpaa149","journal-title":"Am J Hypertens"},{"issue":"3","key":"303_CR68","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.120.15464","volume":"76","author":"M Son","year":"2020","unstructured":"Son M, Seo J, Yang S (2020) Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea. Hypertension 76(3):742\u2013749. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15464","journal-title":"Hypertension"},{"issue":"3","key":"303_CR69","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","volume":"159","author":"ND Tan","year":"2020","unstructured":"Tan ND, Qiu Y, Xing XB, Ghosh S, Chen MH, Mao R (2020) Associations between angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19. Gastroenterology 159(3):1170-1172.e1. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.034","journal-title":"Gastroenterology"},{"key":"303_CR70","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhang D, Wang S, Jin Y, Huan J, Wu Y, Xia C, Li Z, Qi X, Zhang D, Han X, Zhu X, Qu Y, Wang Q (2020) A retrospective study from 2 centers in china on the effects of continued use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with hypertension and COVID-19. Med Sci Monit 26:e926651. https:\/\/doi.org\/10.12659\/MSM.926651","DOI":"10.12659\/MSM.926651"},{"issue":"5","key":"303_CR71","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11684-020-0800-y","volume":"14","author":"J Xu","year":"2020","unstructured":"Xu J, Huang C, Fan G, Liu Z, Shang L, Zhou F, Wang Y, Yu J, Yang L, Xie K, Huang Z, Huang L, Gu X, Li H, Zhang Y, Wang Y, Hayden FG, Horby PW, Cao B, Wang C (2020) Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med 14(5):601\u2013612. https:\/\/doi.org\/10.1007\/s11684-020-0800-y","journal-title":"Front Med"},{"issue":"1","key":"303_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","volume":"76","author":"G Yang","year":"2020","unstructured":"Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai J, Yang R, Han J, Huang Y, He S (2020) Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension 76(1):51\u201358. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15143","journal-title":"Hypertension"},{"issue":"5","key":"303_CR73","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jinf.2020.08.014","volume":"81","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Liu D, Zeng S, Wang S, Xu S, Wang Y, Yu R, Gao Y, Li H, Feng X, Zhou N, Zhao C, Gao Q (2020) In-hospital use of ACEI\/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension. J Infect 81(5):816\u2013846. https:\/\/doi.org\/10.1016\/j.jinf.2020.08.014","journal-title":"J Infect"},{"key":"303_CR74","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.06.20054825","author":"Z Zeng","year":"2020","unstructured":"Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H (2020) Hypertension in patients hospitalized with COVID-19 in Wuhan, China: a single-center retrospective observational study. MedRxiv. https:\/\/doi.org\/10.1101\/2020.04.06.20054825","journal-title":"MedRxiv"},{"issue":"12","key":"303_CR75","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Loomba R, Liu PP, Li H (2020) Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 126(12):1671\u20131681. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317134","journal-title":"Circ Res"},{"issue":"12","key":"303_CR76","doi-asserted-by":"publisher","first-page":"300060520979151","DOI":"10.1177\/0300060520979151","volume":"48","author":"Y Zhong","year":"2020","unstructured":"Zhong Y, Zhao L, Wu G, Hu C, Wu C, Xu M, Dong H, Zhang Q, Wang G, Yu B, Lv J, Wu C, Zhang S, Cao C, Shu L, Pan Y, Liu X, Wu F (2020) Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study. J Int Med Res 48(12):300060520979151. https:\/\/doi.org\/10.1177\/0300060520979151","journal-title":"J Int Med Res"},{"issue":"2","key":"303_CR77","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1161\/HYPERTENSIONAHA.120.15622","volume":"76","author":"F Zhou","year":"2020","unstructured":"Zhou F, Liu YM, Xie J, Li H, Lei F, Yang H, Qin JJ, Cai J, Zhang XJ, Wu B, Xia M, Xiang D, Yang C, Ma X, Xu Q, Lu Z, Lu H, Xia X, Wang D, Liao X, Peng G, Yang J, Huang X, Zhang BH, Yuan Y, Wei X, Liu PP, Wang Y, Zhang P, She ZG, Xia J, Li H (2020) Comparative impacts of ACE (angiotensin-converting enzyme) inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality. Hypertension 76(2):e15\u2013e17. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15622","journal-title":"Hypertension"},{"issue":"20","key":"303_CR78","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111(20):2605\u20132610. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.510461","journal-title":"Circulation"},{"key":"303_CR79","doi-asserted-by":"publisher","unstructured":"Dai XC, An ZY, Wang ZY, Wang ZZ, Wang YR. (2021) Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies. Front Cardiovasc Med 8:609857. https:\/\/doi.org\/10.3389\/fcvm.2021.609857","DOI":"10.3389\/fcvm.2021.609857"},{"issue":"8","key":"303_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.703661","volume":"10","author":"R Singh","year":"2022","unstructured":"Singh R, Rathore SS, Khan H, Bhurwal A, Sheraton M, Ghosh P, Anand S, Makadia J, Ayesha F, Mahapure KS, Mehra I, Tekin A, Kashyap R, Bansal V (2022) Mortality and severity in COVID-19 patients on ACEIs and ARBs\u2014a systematic review, meta-analysis, and meta-regression analysis. Front Med (Lausanne) 10(8):703661. https:\/\/doi.org\/10.3389\/fmed.2021.703661","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"303_CR81","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40256-020-00439-5","volume":"20","author":"SS Hasan","year":"2020","unstructured":"Hasan SS, Kow CS, Hadi MA, Zaidi STR, Merchant HA (2020) Mortality and disease severity among COVID-19 patients receiving renin\u2013angiotensin system inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs 20(6):571\u2013590. https:\/\/doi.org\/10.1007\/s40256-020-00439-5","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"303_CR82","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/jmv.26625","volume":"93","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S, Xiao X, Qin Q (2021) The use of renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis. J Med Virol 93(3):1370\u20131377. https:\/\/doi.org\/10.1002\/jmv.26625","journal-title":"J Med Virol"},{"key":"303_CR83","doi-asserted-by":"publisher","DOI":"10.2174\/1573402118666220407093332","author":"GN Azad","year":"2022","unstructured":"Azad GN, Kumar A (2022) ACEi\/ARB and deaths of COVID-19 patients. Curr Hypertens Rev. https:\/\/doi.org\/10.2174\/1573402118666220407093332","journal-title":"Curr Hypertens Rev"},{"key":"303_CR84","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14515","volume":"75","author":"R Srivastava","year":"2021","unstructured":"Srivastava R, Kumar A (2021) Use of aspirin in reduction of mortality of COVID-19 patients: a meta-analysis. Int J Clin Pract 75:e14515. https:\/\/doi.org\/10.1111\/ijcp.14515","journal-title":"Int J Clin Pract"},{"key":"303_CR85","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1021\/acschemneuro.1c00353","volume":"12","author":"D Vitalakumar","year":"2021","unstructured":"Vitalakumar D, Sharma A, Kumar A, Flora SJS (2021) Neurological Manifestations in COVID-19 Patients: a meta-analysis. ACS Chem Neurosci 12:2776\u20132797. https:\/\/doi.org\/10.1021\/acschemneuro.1c00353","journal-title":"ACS Chem Neurosci"},{"key":"303_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174579","volume":"914","author":"M Thakur","year":"2022","unstructured":"Thakur M, Datusalia AK, Kumar A (2022) Use of steroids in COVID-19 patients: a meta-analysis. Eur J Pharmacol 914:174579. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174579","journal-title":"Eur J Pharmacol"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-022-00303-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-022-00303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T22:08:18Z","timestamp":1662502098000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-022-00303-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1186\/s43044-022-00303-8","relation":{},"ISSN":["2090-911X"],"issn-type":[{"type":"electronic","value":"2090-911X"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}